JP2023016969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023016969A5 JP2023016969A5 JP2022195529A JP2022195529A JP2023016969A5 JP 2023016969 A5 JP2023016969 A5 JP 2023016969A5 JP 2022195529 A JP2022195529 A JP 2022195529A JP 2022195529 A JP2022195529 A JP 2022195529A JP 2023016969 A5 JP2023016969 A5 JP 2023016969A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 210000003169 central nervous system Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 6
- 238000007914 intraventricular administration Methods 0.000 claims 4
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 102000048770 human CD276 Human genes 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 201000002035 ovary rhabdomyosarcoma Diseases 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505558P | 2017-05-12 | 2017-05-12 | |
| US62/505,558 | 2017-05-12 | ||
| JP2020513491A JP2020520382A (ja) | 2017-05-12 | 2018-05-14 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
| PCT/US2018/032559 WO2018209346A1 (en) | 2017-05-12 | 2018-05-14 | Use of anti-b7h3 antibodies for treating cancer in the central nervous system |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513491A Division JP2020520382A (ja) | 2017-05-12 | 2018-05-14 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023016969A JP2023016969A (ja) | 2023-02-02 |
| JP2023016969A5 true JP2023016969A5 (enExample) | 2023-07-25 |
Family
ID=64102794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513491A Pending JP2020520382A (ja) | 2017-05-12 | 2018-05-14 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
| JP2022195529A Pending JP2023016969A (ja) | 2017-05-12 | 2022-12-07 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513491A Pending JP2020520382A (ja) | 2017-05-12 | 2018-05-14 | 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200197546A1 (enExample) |
| EP (1) | EP3635012A4 (enExample) |
| JP (2) | JP2020520382A (enExample) |
| KR (1) | KR20200008580A (enExample) |
| CN (1) | CN110799542A (enExample) |
| AU (1) | AU2018265888A1 (enExample) |
| BR (1) | BR112019023776A2 (enExample) |
| CA (1) | CA3062335A1 (enExample) |
| EA (1) | EA201992683A1 (enExample) |
| RU (1) | RU2019140833A (enExample) |
| WO (1) | WO2018209346A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113853220A (zh) * | 2019-03-11 | 2021-12-28 | 生物相容英国有限公司 | 用于中枢神经系统肿瘤治疗的放射性微球 |
| EP4022313A1 (en) | 2019-08-30 | 2022-07-06 | Y-Mabs Therapeutics, Inc. | Immunohistochemical assessment of b7-h3 expression |
| WO2021190586A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | B7h3抗体-依喜替康类似物偶联物及其医药用途 |
| CN117024590A (zh) * | 2020-04-22 | 2023-11-10 | 复星凯特生物科技有限公司 | 抗人b7-h3的单克隆抗体及其应用 |
| EP4138931A1 (en) | 2020-04-24 | 2023-03-01 | Y-Mabs Therapeutics, Inc. | B7h3 antibodies with chelators |
| CN112961241B (zh) * | 2020-06-30 | 2022-04-22 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| WO2022167052A1 (en) * | 2021-02-08 | 2022-08-11 | Y-Mabs Therapeutics, Inc. | Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies |
| KR20230145038A (ko) | 2021-02-09 | 2023-10-17 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | 생물활성 물질 접합체, 이의 제조방법 및 이의 용도 |
| US20240199750A1 (en) | 2021-03-26 | 2024-06-20 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| KR20240019297A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
| US20240392007A1 (en) * | 2021-09-27 | 2024-11-28 | Shenghe (China) Biopharmaceutical Co., Ltd. | Heterodimeric protein and application thereof |
| EP4480499A1 (en) | 2022-02-16 | 2024-12-25 | Medilink Therapeutics (Suzhou) Co., Ltd. | Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof |
| CN119212733A (zh) | 2022-05-18 | 2024-12-27 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| WO2024008039A1 (zh) * | 2022-07-08 | 2024-01-11 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体融合蛋白及其应用 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| JP2010523478A (ja) * | 2007-03-22 | 2010-07-15 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | モノクローナル抗体８ｈ９の使用 |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| BR112017003582B1 (pt) * | 2014-08-27 | 2024-01-09 | Memorial Sloan Kettering Cancer Center | Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico |
| WO2016106004A1 (en) * | 2014-12-23 | 2016-06-30 | Full Spectrum Genetics, Inc. | Novel anti-b7h3 binding compounds and uses thereof |
-
2018
- 2018-05-14 EA EA201992683A patent/EA201992683A1/ru unknown
- 2018-05-14 US US16/613,028 patent/US20200197546A1/en not_active Abandoned
- 2018-05-14 JP JP2020513491A patent/JP2020520382A/ja active Pending
- 2018-05-14 CN CN201880040310.2A patent/CN110799542A/zh active Pending
- 2018-05-14 RU RU2019140833A patent/RU2019140833A/ru unknown
- 2018-05-14 EP EP18797639.4A patent/EP3635012A4/en not_active Withdrawn
- 2018-05-14 BR BR112019023776-3A patent/BR112019023776A2/pt unknown
- 2018-05-14 KR KR1020197036884A patent/KR20200008580A/ko not_active Ceased
- 2018-05-14 WO PCT/US2018/032559 patent/WO2018209346A1/en not_active Ceased
- 2018-05-14 CA CA3062335A patent/CA3062335A1/en active Pending
- 2018-05-14 AU AU2018265888A patent/AU2018265888A1/en not_active Abandoned
-
2022
- 2022-12-07 JP JP2022195529A patent/JP2023016969A/ja active Pending
-
2024
- 2024-01-24 US US18/421,157 patent/US20240415990A1/en active Pending